Perjeta®
Understanding Perjeta®
Perjeta® (pertuzumab) is a prescription medicine indicated, in specific treatment settings and regimens, for certain adults with HER2-positive breast cancer. Perjeta® is indicated for use in combination with trastuzumab and docetaxel for the treatment of adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease; in combination with trastuzumab and chemotherapy as neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; and for the adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence. HER2 testing should be performed using FDA-approved tests by laboratories with demonstrated proficiency. Perjeta® is a HER2/neu receptor antagonist administered by intravenous infusion. Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of HER2 and inhibits ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4.
How Perjeta® Works:
- Targets the HER2 receptor: Perjeta® contains pertuzumab, a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of HER2.
- Inhibits HER2 heterodimerization: Pertuzumab inhibits ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4.
- Inhibits downstream signaling: Pertuzumab inhibits downstream signaling through two major signaling pathways, MAP kinase and phosphoinositide 3-kinase (PI3K).
- Demonstrates antibody-dependent cellular cytotoxicity (ADCC): Pertuzumab mediates antibody-dependent cellular cytotoxicity (ADCC) in vitro.
For more information, please visit the Perjeta® patient website. Speak with your healthcare provider to determine if Perjeta® is the right treatment option for you.
Referral Form: |
WHAT IT TREATS: |
MANUFACTURER: Genentech, Inc.
|
CLASS: HER2/neu receptor antagonist (monoclonal antibody) |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: Intravenous (IV) infusion |
|
FREQUENCY: Every 3 weeks |
Length of infusion: 30 to 60 minutes, depending on dose number and patient tolerability. Initial infusion is typically 90 minutes. |
FOR MORE INFORMATION: |
















